At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 124 enrolled
Drug / intervention
MHAA4549A +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, Administered as Monotherapy for the Treatment of Acute Uncomplicated Seasonal Influenza A Infection in Otherwise Healthy Adults
In Brief
A Phase 2 clinical trial evaluating MHAA4549A and Placebo for Influenza A. Completed, enrolled 124 participants across 80 sites in 7 countries.
Detailed Summary
This is a Phase 2, randomized, double-blind, placebo-controlled single dose study in otherwise healthy adults with acute uncomplicated seasonal influenza A to assess the safety and tolerability, efficacy, and pharmacokinetics of MHAA4549A.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza A
CountriesCanada, New Zealand, South Africa, South Korea, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 2015
Enrollment StartOct 2016
Primary CompletionNov 2017
TodayJul 2026
First PostedDec 7, 2015
Enrollment StartOct 12, 2016
Primary CompletionNov 13, 2017
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 10.6 years ago
Interventions
MHAA4549Adrug
MHAA4549A will be administered as a single dose by IV administration.
Placebodrug
Placebo will be administered as a single dose by IV administration.